- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03474393
A Evaluation of Systematic Intensive Therapy Using CGM/FGM in Clinical Diabetes Care
A Randomised Trial of Evaluating a Systematic Intensive Therapy Using Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring (FGM) in Clinical Diabetes Care
This study aims to analyse if intensive systematic treatment via internet and telephone during 4 months improved HbA1c for persons with type 1 diabetes which are already treated with CGM or FGM, and if the effect continuous for 1-2 years after the intervention stops. Time in Hypoglycaemia, treatment satisfaction, Diabetes distress and hypoglycaemia fear will even be analysed.
A randomised, non-blinded, multi-centre, clinical study for persons with type 1 diabetes and hbA1c ≥ 58mmol/mol and treated with CGM or FGM.
The control group continuous its normal diabetes care with study visits at randomisation, 10, 18, 32, and 52 weeks for HbA1c and to fill in questionnaires.
The intervention group will have contact with the study team on a weekly basis, when mean blood glucose levels the previous week are elevated. They will receive help with analysing data and advice on how to improve their glucose values. They will even meet the study team at randomisation, 10, 18, 32, and 52 weeks for HbA1c and to fill in questionnaires.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Uddevalla, Sweden
- NU-Hosptial Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent obtained before trial-related activities (i.e., any activity that would not have been performed during routine patient management)
- Clinical diagnosis of Type 1 diabetes
- Adult patients over 18 years of age
- HbA1c ≥ 58 mmol/mol
- Currently using CGM or FGM
- To have a possibility to download and share FGM/CGM data
Exclusion Criteria:
- Type 2 diabetes
- Diabetes duration <1 year
- Long-term Systemic glucocorticoid treatment during the last 3 months
- Planned or changed treatment the last 3 months regarding MDI vs. Insulin pump or added or stopped CGM or FGM therapy
- Current or planned pregnancy or breastfeeding during the next 12 months
- Planned move during the next 12 months making it not possible to participate in study activities
- Other reason determined by the investigator not being appropriate for participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Normal diabetes care
Continue with their normal diabetes care.
Come in for control visits
|
|
Experimental: Systematic intensive therapy
Intensive Internet and telephone contact for 4 months and Control visits
|
intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c
Time Frame: from baseline to 18 weeks
|
Change in HbA1c from baseline to week 18
|
from baseline to 18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in Range
Time Frame: from baseline to 18 weeks
|
Change in Time in Range (4-10mmol/l) and from Baseline to week 18
|
from baseline to 18 weeks
|
Mean glucose levels
Time Frame: from baseline to 18 weeks
|
Change in mean glucose levels from baseline to 18
|
from baseline to 18 weeks
|
Time above range
Time Frame: from baseline to 18 weeks
|
Change in time above range (glucose values above 10mmol/L) from baseline to 18 weeks
|
from baseline to 18 weeks
|
HbA1c at week 32
Time Frame: From baseline to 18 weeks
|
Change in HbA1c from baseline to week 32
|
From baseline to 18 weeks
|
HbA1c at week 52
Time Frame: From baseline to 52 weeks
|
Change in HbA1c from baseline to week 52
|
From baseline to 52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Glucose at week 32 and 52
Time Frame: From baseline to 32 and 52 weeks
|
Change in mean glucose from baseline to week 32 and 52
|
From baseline to 32 and 52 weeks
|
Time below range week 18, 32 and 52
Time Frame: From baseline to 18, 32 and 52 weeks
|
Change in time below range (glucose values below 4.0mmol/l) from baseline to week 18, 32 and 52
|
From baseline to 18, 32 and 52 weeks
|
Time above range weeks 32 and 52
Time Frame: From baseline to weeks 32 and 52
|
Change in time above range from baseline to 32 and 52 weeks
|
From baseline to weeks 32 and 52
|
Glycaemic variability - Standard deviation
Time Frame: From baseline to weeks 18, 32 and 52
|
Change in glycaemic variability from baseline to 18, 32 and 52 weeks using Standard deviation
|
From baseline to weeks 18, 32 and 52
|
Glycaemic variability - Coefficient of variation
Time Frame: From baseline to weeks 18, 32 and 52
|
Change in glycaemic variability from baseline to 18, 32 and 52 weeks using Coefficient of variation
|
From baseline to weeks 18, 32 and 52
|
Glycaemic variability - Mage
Time Frame: From baseline to weeks 18, 32 and 52
|
Change in glycaemic variability from baseline to 18, 32 and 52 weeks using MAGE
|
From baseline to weeks 18, 32 and 52
|
DTSQ
Time Frame: From baseline to weeks 18, 32 and 52
|
Change in Diabetes Treatment and satisfaction (DTSQ) score from baseline to 18, 32 and 52 weeks.
DDS is a 6 pt Lickert scale with 28 questions
|
From baseline to weeks 18, 32 and 52
|
Hypoglycaemic confidence
Time Frame: From baseline to weeks 18, 32 and 52
|
Change in Hypoglycaemic confidence score from baseline to 18 and 52 weeks.
The hypoglycemic confidence scale is a 4pt Lickert scale with 9 questions
|
From baseline to weeks 18, 32 and 52
|
Diabetes distress scale
Time Frame: From baseline to weeks 18, 32 and 52
|
Change in Diabetes distress score (DDS) score from baseline to 18 and 52 weeks.
DDS is a 6 pt Lickert scale with 28 questions
|
From baseline to weeks 18, 32 and 52
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIT-CGM/FGM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type1diabetes
-
Silesian Centre for Heart DiseasesThe Jerzy Kukuczka Academy of Physical Education in KatowiceCompletedtype1diabetesPoland
-
Rabin Medical CenterThe Leona M. and Harry B. Helmsley Charitable Trust; DreaMed DiabetesRecruiting
-
University of Southern CaliforniaThe Leona M. and Harry B. Helmsley Charitable TrustCompletedType1diabetesUnited States
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Active, not recruiting
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandCompletedType1diabetes | Hemodialysis | Type2DiabetesDenmark
-
Vastra Gotaland RegionRecruitingType1diabetes | Psychology Functional BehaviorSweden
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Active, not recruitingHypoglycemia | Type1diabetes | Islet Cell Transplantation | Hypoglycemia UnawarenessUnited States
-
University of British ColumbiaJuvenile Diabetes Research Foundation; Brain CanadaNot yet recruiting
-
Pacific Diabetes TechnologiesRecruiting
Clinical Trials on systematic intensive therapy
-
Chinese PLA General HospitalNot yet recruitingPancreatic Neoplasms | Ablation
-
Zeng ChanghaoThe First Affiliated Hospital of Zhengzhou UniversityTerminatedDysphagia | Pierre-Robin SyndromeChina
-
University of AlcalaEuropean University SpainCompleted
-
Riphah International UniversityCompleted
-
Loewenstein HospitalTechnion, Israel Institute of TechnologyRecruiting
-
US Department of Veterans AffairsBristol-Myers Squibb; Sanofi; GE Healthcare; Merck Sharp & Dohme LLC; Pfizer; Astra... and other collaboratorsCompletedMyocardial IschemiaUnited States, Canada
-
Laval UniversityRecruiting
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchUnknownPost-Stroke Chronic Aphasia | Anomia (Word-retrieval Impairment)Germany
-
University of WashingtonNational Institute of Mental Health (NIMH)Completed